- Patent Title: Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
-
Application No.: US14807522Application Date: 2015-07-23
-
Publication No.: US09546216B2Publication Date: 2017-01-17
- Inventor: Alan J. Korman , Mark J. Selby , Changyu Wang , Mohan Srinivasan , David B. Passmore , Haichun Huang , Haibin Chen
- Applicant: E. R. Squibb & Sons, L. L. C.
- Applicant Address: US NJ Princeton
- Assignee: E.R. Squibb & Sons, L. L. C.
- Current Assignee: E.R. Squibb & Sons, L. L. C.
- Current Assignee Address: US NJ Princeton
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61K47/48 ; A61K39/00

Abstract:
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
Public/Granted literature
- US09580505B2 Human monoclonal antibodies to programmed death ligand 1 (PD-L1) Public/Granted day:2017-02-28
Information query